ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASIVE CANDIDIASIS AND PROPHYLAXIS OF INVASIVE FUNGAL DISEASE AS ORAL AND IC FORMULA
$18,454,788
| Recipient | SCYNEXIS INC UEI H6PSJYEW3DT9 |
|---|---|
| Award ID | 75A50126C00007 |
| Award amount | $18,454,788 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response |
| NAICS | 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| PSC | AN13 |
| Set-aside | Unrestricted |
| Start date | Sep 15, 2026 |
| End date | Jul 31, 2032 |
| Place of performance | JERSEY CITY, NJ |
| Record updated | Sep 25, 2026 |
View the official award record
Our catalog shows awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. $0 today for 14 days (card required), then $49.99/month.
Search open bids